Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
Conditions
Melanoma - Non Small Cell Lung Cancer - Small Cell Lung Cancer
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms - Small Cell Lung Carcinoma
Study Type
Interventional
Study Phase
N/A
Study Design
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
Intervention
Name: Blood sample Type: Procedure
Name: Tumorous biopsy Type: Procedure
Name: Healthy material sample Type: Procedure
Overall Status
Recruiting
Summary
Lung Cancer and melanoma relapsed frequently whereas its very sensitive to treatment such as chemotherapy or radiotherapy. The purpose of this study is to have a better understanding of why those patients are relapsing using next generation sequencing to identify rare mutations and assessed their predictive value.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

1. Cytological or histological diagnosis of SCLC, NSCLC or melanoma

2. Patients age >/= 18 years old

3. Indication of treatment using platinum salts for lung cancer except for patient with NSCLC treated by surgery for whom platinum salts is not indicated

4. If a biopsy is proposed, lesion lust be easily accessible

5. Signed informed consent

Exclusion Criteria:

1. Patients unable to follow the protocol

2. Consent refusal
Location
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, France
Status: Recruiting
Contact: Benjamin Besse, MD - 0142114317 - benjamin.besse@gustaveroussy.fr
Start Date
July 2009
Completion Date
July 2019
Sponsors
Gustave Roussy, Cancer Campus, Grand Paris
Source
Gustave Roussy, Cancer Campus, Grand Paris
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page